Cabozantinib demonstrates immunomodulatory activity and targets multiple receptor tyrosine kinases involved in tumour pathogenesis, including the pro-angiogenic growth factor receptors VEGFR and MET, as well as the TAM family of kinases (TYRO3, AXL, MER), which contribute to immunosuppression in the tumour microenvironment.29 The gene discussed is AXL; the disease is neoplasm.